---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-061609"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:48:57.948949+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sagimet Q1 2024 net loss $6.6M; cash $193.7M; FDA End-of-Phase 2 meeting in Q2; MASH Phase 3 start H2

## Summary
- Net loss for Q1 2024 was $6.6M, flat year-over-year; R&D expense $5.3M, G&A $3.5M.
- Cash, cash equivalents and marketable securities total $193.7M as of March 31, 2024, expected to fund operations through 2025.
- Denifanstat Phase 2b FASCINATE-2 full data to be presented as oral at EASL June 5-8, 2024.
- End-of-Phase 2 meeting with FDA anticipated in Q2 2024; Phase 3 trial start planned for second half of 2024.
- Follow-on offering in January 2024 netted $104.7M to support pipeline and general corporate purposes.

## SEC filing metadata
- accession: 0001104659-24-061609
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465924061609/0001104659-24-061609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465924061609/tm2414482d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-061609
- JSON: https://secwatch.observer/filing/0001104659-24-061609.json
- Plain text: https://secwatch.observer/filing/0001104659-24-061609.txt

## Key facts
- Earnings Releases
  Sagimet Biosciences Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter ended March 31, 2024 was $6.6 million compared to a net loss of $6.6 million for the firs.
  - Period: the quarter ended March 31, 2024
  - Net income: Net loss for the first quarter ended March 31, 2024 was $6.6 million compared to a net loss of $6.6 million for the firs
  - Result: reported results
  source text: today reported financial results for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465924061609/0001104659-24-061609-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.